Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancersadmin2021-02-11T19:51:54+00:00November 25th, 2020|Read More
Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten statusadmin2021-02-11T19:57:34+00:00November 22nd, 2020|Read More
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testingadmin2021-02-17T18:10:07+00:00November 17th, 2020|Read More
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaadmin2021-02-11T20:05:42+00:00October 30th, 2020|Read More
Plasticity of the human IgM repertoire in response to long‐term spaceflightadmin2021-02-11T20:09:45+00:00October 13th, 2020|Read More
Invivoscribe appoints Loui Madakamutil to lead its Therapeutics division as Chief Scientific Officer.admin2021-02-26T19:09:31+00:00September 8th, 2020|Read More
Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemiaadmin2021-02-26T19:09:41+00:00July 14th, 2020|Read More
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United Statesadmin2021-02-26T19:09:52+00:00May 19th, 2020|Read More
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.admin2021-02-26T19:10:05+00:00May 12th, 2020|Read More
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assayadmin2021-02-26T19:36:03+00:00December 5th, 2019|Read More
